Cannabis Use Disorder Market Report 2026

The cannabis use disorder market size has grown strongly in recent years. It will grow from $1.65 billion in 2025 to $1.78 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing prevalence of cannabis consumption, rising awareness of substance use disorders, expansion of rehabilitation infrastructure, greater recognition of mental health disorders, availability of behavioral therapy frameworks.

The cannabis use disorder market size is expected to see strong growth in the next few years. It will grow to $2.35 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing acceptance of digital mental health solutions, rising investments in addiction research, expansion of telehealth-based treatment models, growing focus on outcome-based care, increasing integration of pharmacotherapy and behavioral therapy. Major trends in the forecast period include increasing adoption of integrated behavioral and pharmacological treatments, rising focus on personalized addiction therapy programs, growing use of digital therapeutics and remote monitoring, expansion of multidisciplinary treatment approaches, enhanced emphasis on early diagnosis and intervention.

The growing awareness and diagnosis of cannabis addiction are expected to drive the expansion of the cannabis use disorder market in the coming years. Awareness and diagnosis of cannabis addiction involve informing the public, healthcare providers, and individuals about the signs, symptoms, and risks associated with cannabis use disorder (CUD). The rise in awareness and diagnosis of cannabis addiction is fueled by several factors, including increased legalization and availability of cannabis, as well as growing scientific and medical acknowledgment. Treatment for cannabis use disorder provides a structured approach to managing withdrawal symptoms, reducing cravings, and addressing underlying psychological factors, which directly supports the diagnosis of cannabis addiction by offering clinical evidence of dependency patterns, highlighting the severity of the disorder, and guiding the appropriate level of intervention tailored to the individual's specific needs. For example, in November 2024, according to the Office for Health Improvement and Disparities, a UK-based government agency, the proportion of new entrants seeking treatment for cannabis-related issues remained relatively stable, increasing slightly by 0.5 percentage points from 20.9% to 21.4%. At the same time, the number of new entrants with benzodiazepine-related problems rose from 3,620 in 2022-2023 to 3,872 this year. Therefore, the increasing awareness and diagnosis of cannabis addiction are contributing to the growth of the cannabis use disorder market.

Major companies in the cannabis use disorder (CUD) market are concentrating on developing innovative solutions, including digital therapeutics and technology-enabled behavioral intervention platforms, to assist individuals in reducing or ceasing problematic cannabis use through structured counseling, personalized care plans, and continuous support. Digital therapeutics for CUD treatment involve clinically validated, technology-based programs that deliver behavioral therapies, monitor progress, and offer remote access to licensed clinicians to enhance adherence and long-term recovery outcomes. For example, in April 2024, Pelago, a US-based virtual clinic focused on substance use management, launched a cannabis use disorder (CUD) treatment program aimed at addressing the rising number of individuals affected by the condition, estimated at nearly 18 million adults in the U.S. Pelago’s program provides education on cannabis use and delivers evidence-based therapies, such as cognitive behavioral therapy and motivational enhancement therapy, while also supporting adolescents aged 15-17 through abstinence-oriented treatment goals.

In January 2025, Lantern, a US-based specialty care platform, partnered with Pelago to broaden access to substance use disorder treatment. The collaboration seeks to streamline healthcare benefits for Lantern's employer clients and offer more individuals access to substance use disorder support. Pelago is a US-based digital clinic that offers a cannabis use disorder treatment solution.

Major companies operating in the cannabis use disorder market are Lyra Health Inc., Pyramid Healthcare Inc., Hazelden Betty Ford Foundation, Charlie Health, Caron Treatment Center, Promises Behavioral Health, Sierra Tucson, Samarpan, Affect Therapeutics Inc., Cadabam's Rehabilitation Center, Aelis Farma, Skywood Recovery, Pelago, PleoPharma Inc., Abhasa, Marijuana Anonymous, Northpoint Colorado, Sukoon Health, Granite Mountain Behavioral Healthcare, GreeneStone.

North America was the largest region in the cannabis use disorder market in 2025. The regions covered in the cannabis use disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cannabis use disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cannabis use disorder market indirectly by increasing costs of imported pharmaceutical ingredients, digital health devices, diagnostic tools, and medical software used in treatment and monitoring programs. Healthcare providers in North America and Europe are most affected due to reliance on cross-border pharmaceutical supply chains and technology imports, while Asia-Pacific faces higher costs for digital health infrastructure deployment. These tariffs contribute to higher treatment delivery costs and slower adoption of advanced therapeutic solutions. However, they are also encouraging domestic drug manufacturing, local software development, and regional clinical research initiatives that strengthen long-term treatment accessibility and resilience.

The cannabis use disorder market research report is one of a series of new reports that provides cannabis use disorder market statistics, including cannabis use disorder industry global market size, regional shares, competitors with a cannabis use disorder market share, detailed cannabis use disorder market segments, market trends and opportunities, and any further data you may need to thrive in the cannabis use disorder industry. This cannabis use disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cannabis use disorder (CUD) is a condition marked by the problematic or excessive consumption of cannabis, resulting in significant impairment or distress. It is categorized as a type of substance use disorder and arises when an individual cannot control or reduce their cannabis use despite experiencing negative consequences.

The primary approaches to treating cannabis use disorder are pharmacotherapy and behavioral therapies. Pharmacotherapy for cannabis use disorder involves the use of medications to relieve withdrawal symptoms, reduce cravings, and support recovery. These medications can be administered through various routes, including oral, transdermal, inhalation, and sublingual methods, and are utilized by multiple end-users such as hospitals, specialty clinics, rehabilitation centers, and homecare settings.

The cannabis use disorder market consists of revenues earned by entities by providing services such as inpatient and outpatient treatment programs, behavioral therapies, digital health solutions and education programs, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cannabis use disorder market also includes sales of diagnostic tools and pharmaceutical products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.